All News
Filter News
Found 808,679 articles
-
Nephron Announces Hiring of Key Executives
10/24/2023
Nephron Pharmaceuticals Corporation announced the new hiring of six key executives.
-
Q32 Bio Appoints Saul Fink, Ph.D. as Chief Technology Officer
10/24/2023
Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, announced the appointment of Saul Fink, Ph.D., as Chief Technology Officer.
-
Centene Corporation Reports Third Quarter 2023 Results
10/24/2023
Centene Corporation announced its financial results for the third quarter ended September 30, 2023.
-
SciSparc Granted Patent for its Core Technology From the Australian Patent Office
10/24/2023
SciSparc Ltd. announced today that it received a notice of acceptance for its patent application for the Combinations of Cannabinoids and N-Acylethanolamines (the “Patent”).
-
Taysha Gene Therapies Presents New Preclinical In-vitro Data on TSHA-102 in Rett Syndrome Supporting miRARE Regulation of MECP2 Expression at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress
10/24/2023
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), today announced new preclinical in vitro data on TSHA-102 in Rett syndrome as part of a poster presentation at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress.
-
Avenge Bio to Present at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
10/24/2023
Avenge Bio, Inc. today announced their poster presentation at the Society of Immunotherapy of Cancer 38th Annual Meeting (SITC 2023) on November 1-5, 2023, in San Diego, California.
-
Rancho BioSciences Webinar: Unpacking Unstructured Data: Extracting Insights From Neuropathological Reports of Parkinson’s Disease Patients Using Large Language Models
10/24/2023
Rancho Biosciences, the premier Data Science Services company headquartered in San Diego, California, is thrilled to extend a warm invitation to LLM enthusiasts, experts, and professionals in the Life Sciences sector.
-
Therini Bio Announces Interim Results from the Phase 1 Trial of THN391 for the Potential Treatment of Dementia
10/24/2023
Therini Bio, Inc. , today announced interim results from the Phase 1 trial of its lead candidate, THN391, for the treatment of dementia.
-
Nutcracker Therapeutics to Present Data for Two mRNA Drug Candidates at SITC 2023
10/24/2023
Nutcracker Therapeutics, Inc. today announced two poster presentations: one on the company’s lead mRNA therapeutic candidate, NTX-250, which targets human papillomavirus (HPV)-driven cancers; the other on its latest therapeutic candidate, NTX-471, which targets CD47 and CCR4.
-
Zevia to Announce Third Quarter 2023 Results on Tuesday, November 7, 2023
10/24/2023
Zevia PBC (“Zevia”) (NYSE:ZVIA) today announced that it will release its financial results for the third quarter ended September 30, 2023 before the market open on Tuesday, November 7, 2023 followed by a conference call at 8:30 a.m. Eastern Time to discuss the results.
-
bluebird bio to Host Third Quarter 2023 Financial Results Conference Call
10/24/2023
bluebird bio, Inc. (Nasdaq: BLUE) announced today that it will host a conference call to discuss third quarter 2023 financial results and business updates on Tuesday, November 7 at 8:00 a.m. ET.
-
Aclarion Announces Nociscan® Cost-Effectiveness Poster Presented at 45th Annual SMDM Meeting
10/24/2023
Nociscan cost-effectiveness abstract poster highlights dominance over provocative discography. The 45th Annual Society for Medical Decision Making (SMDM) Meeting is being held October 22-25, 2023.
-
Neuronetics to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call
10/24/2023
Neuronetics, Inc. today announced that it plans to release third quarter 2023 financial and operating results prior to market open on Tuesday, November 7th, 2023.
-
Electromed, Inc. Schedules its First Quarter Fiscal 2024 Financial Results Conference Call for November 7, 2023 at 5:00 p.m. ET
10/24/2023
Electromed, Inc. today announced that it will issue its financial results press release for the fiscal 2024 first quarter ended September 30, 2023, on Tuesday, November 7, 2023 after the close of the stock market.
-
Biote Schedules Third Quarter 2023 Financial Results Release and Conference Call
10/24/2023
biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading provider of hormone optimization, today announced the Company will provide third quarter financial results on Tuesday, November 7, 2023, after the close of the market.
-
Elpiscience Announces Three Poster Presentations at Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
10/24/2023
Elpiscience Biopharmaceuticals, Inc. today announced it will have three poster presentations at the SITC 2023 Annual Meeting taking place November 3-5, 2023, in San Diego.
-
RG6501 (OpRegen®) Phase 1/2a Results to Be Featured at Eyecelerator at 2023 American Academy of Ophthalmology (AAO) Annual Meeting
10/24/2023
RG6501 (OpRegen ® ) Phase 1/2a Results to Be Featured at Eyecelerator at 2023 American Academy of Ophthalmology (AAO) Annual Meeting.
-
NeuroTherapia Presents Clinical Data from Phase 1b Clinical Trial of NTRX-07 for the Treatment of Alzheimer’s Disease
10/24/2023
NeuroTherapia, Inc. today announced the presentation of clinical data from its Phase 1b clinical trial of NTRX-07, an oral, small molecule CB2-targeting therapy in development for the treatment of Alzheimer’s disease (AD), in healthy volunteers and a subset of patients with mild cognitive impairment or early AD, at the Clinical Trials on Alzheimer’s Disease (CTAD) conference, taking place in Boston, Mass., Oct. 24-27, 2023.
-
Affinia Therapeutics to Present Preclinical Data on Novel AAV Capsids at the 30th European Society of Gene and Cell Therapy 2023 Annual Congress
10/24/2023
Affinia Therapeutics today announced that the company will present preclinical data on its novel AAV capsids for skeletal muscle, cardiac muscle, and central nervous system (CNS) in a poster session at the 30th European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress, being held October 24-27, 2023, in Brussels, Belgium.
-
Nuvectis Pharma Announces Upcoming Poster Presentation for NXP800 at the 2023 AACR Special Conference on Endometrial Cancer
10/24/2023
Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company") today announced an upcoming scientific presentation for NXP800 at the 2023 AACR Special Conference on Endometrial Cancer (November 16-18, 2023, Boston, MA).